ERBB2 and cancer: The HERACLES trial is a proof-of-concept, multicenter, open-label, phase 2 trial that was performed at four academic cancer centers in Italy to evaluate the efficacy of trastuzumab and lapatinib in patients with HER2-positive, KRAS exon 2 (codons 12 and 13) wild-type mCRC.